Mounjaro (Tirzepatide)
A once-weekly prescription medicine used within a medically supervised metabolic program.
The information on this page has been medically reviewed by
Divine Medica
What is Mounjaro (Tirzepatide)?
Mounjaro contains tirzepatide, a prescription medicine that acts on GIP and GLP-1 receptors. In the EU it is authorized for type 2 diabetes and weight management in eligible adults under defined conditions.
What does Mounjaro (Tirzepatide) entail?
Treatment starts after medical assessment and is given as a once-weekly subcutaneous injection. The dose is increased gradually when appropriate, alongside nutrition, activity and monitoring.
Applications of Mounjaro (Tirzepatide)
Within the current service list, this category may be used for Mounjaro / Tirzepatide Program. The exact product, indication and treatment plan must be confirmed for each patient.
Safety Mounjaro (Tirzepatide)
Nausea, diarrhoea, vomiting, constipation and reduced appetite are common. Screening and follow-up should consider dehydration, pancreatitis or gallbladder symptoms, severe gastrointestinal disease, pregnancy, diabetes medicines and other contraindications in the current product information.
Before and Aftercare
Review weight history, diabetes status, medicines, pregnancy plans, digestive disease, pancreatitis, gallbladder problems and personal goals. Learn injection technique and how to manage missed doses.
Use the prescribed dose only, maintain hydration and follow the nutrition plan. Contact the clinician for persistent vomiting, severe abdominal pain, dehydration, allergic symptoms or low blood sugar when used with relevant diabetes medicines.
Appetite and glucose effects can begin early, while meaningful weight change is assessed over several months. Dose escalation and response vary by individual.
Treatments with Mounjaro (Tirzepatide)
Frequently
asked
questions ›
Find direct answers to questions about Mounjaro (Tirzepatide), safety, treatment planning, and recovery.
Nausea, diarrhoea, vomiting, constipation and reduced appetite are common. Screening and follow-up should consider dehydration, pancreatitis or gallbladder symptoms, severe gastrointestinal disease, pregnancy, diabetes medicines and other contraindications in the current product information.
This is ongoing prescription treatment rather than a one-off procedure. The prescriber reviews benefit, side effects and dose at planned intervals.
Appetite and glucose effects can begin early, while meaningful weight change is assessed over several months. Dose escalation and response vary by individual.
It may be used with other medical care, but all medicines and weight-loss products must be reviewed for interactions, duplication and safety.